A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies Clinical Trial

Official title:
A Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb(Monoclonal Antibody), ESG206 in Subjects With B-cell Lymphoid Malignancies

Status Recruiting

Clinical Trial Summary

This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05822843
Study type	Interventional
Source	Shanghai Escugen Biotechnology Co., Ltd
Contact	Xiaoyan Xing, PhD
Phone	+86 21 5855 6098
Email	xingxiaoyan@escugen.com
Status	Recruiting
Phase	Phase 1
Start date	August 2, 2023
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04684979` - Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies	Phase 2
Not yet recruiting	`NCT05263739` - A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies	Phase 1
Completed	`NCT02569476` - BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies	Phase 1